Skip to main content
TipRanks
Go Ultimate75% OFF

Integrum AB Class B (INTEG.B) AI Stock Analysis

0 Followers
SE:INTEG.B

Integrum AB Class B

(Nasdaq OMX AB:INTEG.B)

Select Model
Rating:49Neutral
Price Target:SEK 8.00â–¼(-2.32% Downside)
Action:reiterated
Date:09/18/26

The score is held down primarily by weak financial performance—unstable profitability, negative gross profit, and ongoing operating/free-cash-flow burn—despite a low-debt balance sheet. Technicals provide a partial offset with price trading above key moving averages and a positive MACD, but valuation support is limited given negative earnings and no stated dividend yield.

Positive Factors
Specialized medical technologyIntegrum operates in a specialized medical-technology niche built around osseointegration, combining implants with surgical solutions and clinical support. This focused model addresses mobility and quality-of-life needs for amputees and can support durable relevance beyond short-term market conditions.
Negative Factors
Severe profitability deteriorationNegative gross profit and deeply negative operating and net margins show that current revenue is not covering the company’s cost base. This weakens earnings quality and indicates that durable value creation depends on restoring gross-margin economics and bringing operating expenses into line with sales.

Integrum AB Class B (INTEG.B) vs. iShares MSCI Sweden ETF (EWD)

-30%-20%-10%0%10%20%30%40%SE:INTEG.B-6.83%EWD+15.64%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 240.25M
Dividend Yield
―
Average Volume (3M)
47.85K
Price to Earnings (P/E)
-5.7
Beta (1Y)
0.87
Revenue Growth
1.43%
EPS Growth
4.98%
Country
Sweden
Employees
33
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Integrum AB Class B Business Overview & Revenue Model

Company Description

Integrum AB (publ) focuses on the research, development, and global sale of advanced bone-anchored prosthetic solutions. A core offering is the Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant system. This innovative bone-...

Integrum AB Class B Financial Statement Overview

Summary

Financials are mixed but skew negative: revenue growth is meaningful, and the balance sheet is strong with very low leverage (debt-to-equity ~1.6%). However, profitability has deteriorated sharply (TTM negative gross profit and deeply negative operating/net margins) and cash generation is weak with materially negative operating cash flow and free cash flow, increasing funding dependence if losses persist.

Income Statement

26Negative

Balance Sheet

72Positive

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMApr 2026Apr 2025Apr 2024Apr 2023Apr 2022
Income Statement
Total Revenue97.81M91.39M91.10M104.12M74.27M55.72M
Gross Profit-1.75M63.23M75.38M91.26M60.84M46.56M
EBITDA-25.61M-39.62M-35.50M8.76M-20.24M2.60M
Net Income-35.50M-46.34M-30.85M4.03M-16.18M21.27M
Balance Sheet
Total Assets199.15M203.60M203.25M164.86M165.17M180.44M
Cash, Cash Equivalents and Short-Term Investments15.01M19.06M39.60M16.90M41.92M75.34M
Total Debt2.74M3.17M4.84M6.42M7.92M580.89K
Total Liabilities24.96M31.59M25.38M22.07M21.64M20.70M
Stockholders Equity174.19M172.01M177.88M142.79M143.53M159.74M
Cash Flow
Free Cash Flow-43.10M-57.96M-50.59M-24.37M-36.50M-49.55M
Operating Cash Flow-33.67M-41.02M-37.70M-12.74M-25.10M-20.28M
Investing Cash Flow-16.44M-16.94M-12.89M-11.63M-11.40M-29.27M
Financing Cash Flow37.92M37.43M73.29M-648.54K3.08M117.23M

Integrum AB Class B Technical Analysis

Technical Analysis SentimentNegative
Last Price8.19

Price Trends

50DMA8.79Negative
100DMA8.62Negative
200DMA8.28Negative

Market Momentum

MACD-0.18Negative
RSI41.58Neutral
STOCH62.77Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:INTEG.B, the sentiment is Negative. The current price of 8.19 is below the 20-day moving average (MA) of 8.36, below the 50-day MA of 8.79, and below the 200-day MA of 8.28, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 41.58 is Neutral, neither overbought nor oversold. The STOCH value of 62.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:INTEG.B.

Integrum AB Class B Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:INTEG.B against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:SECT.BSE:SECT.B74OutperformSEK 62.79B98.4130.26%0.71%13.94%5.70%
SE:GETI.BSE:GETI.B67NeutralSEK 76.70B27.109.13%1.69%-3.90%37.73%
SE:SEZISE:SEZI55NeutralSEK 551.04M-5.65-35.44%―18.56%28.11%
SE:BACTI.BSE:BACTI.B53NeutralSEK 537.92M85.281.93%―-0.51%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:INTEG.BSE:INTEG.B49NeutralSEK 240.25M-5.70-20.71%―1.43%4.98%
SE:OSSDSE:OSSD45NeutralSEK 387.19M-7.74――-11.89%-11.85%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%SE:INTEG.BSE:GETI.BSE:SEZISE:BACTI.BSE:SECT.BSE:OSSDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:INTEG.B and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:INTEG.BIntegrum AB Class B8.19-0.04-0.49%
SE:GETI.BGetinge AB (UK)281.6074.4935.96%
SE:SEZISenzime AB3.50-1.75-33.24%
SE:BACTI.BBactiguard Holding AB15.35-0.55-3.46%
SE:SECT.BSectra AB Class B321.8036.4812.78%
SE:OSSDOssDsign AB3.50-7.48-68.12%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 18, 2026